Actively Recruiting

Phase 2
Age: 6Years - 12Years
All Genders
NCT07390500

Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״

Led by NovaSight · Updated on 2026-02-05

150

Participants Needed

1

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The DYMOND study evaluates the safety and effectiveness of TrackSight™, a digital medical application designed to slow myopia (nearsightedness) progression in children during everyday screen use. TrackSight uses eye-tracking technology to keep central vision clear while subtly adjusting the image in the peripheral viewing area, based on established scientific principles known to influence eye growth. Up to 150 children aged 6 to 12 with myopia will participate at sites in Israel and Hong Kong. All participants will continue wearing their regular single-vision glasses and will be randomly assigned to use TrackSight with or without active visual adjustment for 12 months. Eye examinations and safety assessments will be conducted at the start of the study and after 6 and 12 months. The study aims to determine whether this non-invasive digital approach can safely slow myopia progression in children.

CONDITIONS

Official Title

Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״

Who Can Participate

Age: 6Years - 12Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 6 to 12 years
  • Diagnosed with myopia with cycloplegic spherical or spherical equivalent between -0.75D and -5.00D
  • Astigmatism less than or equal to -1.50D
  • Anisometropia less than 1.50D
  • Visual acuity 20/32 or better in both eyes
  • Interocular visual acuity difference of 1.00 logMAR line or less
  • Generally good health and able to comply with study visits and procedures
  • Regular use of digital devices for at least 1 hour per day as reported by parent
  • Signed informed consent by parent or legal guardian and assent approval
  • Currently wearing single vision refractive correction
Not Eligible

You will not qualify if you...

  • Past or current use of any other myopia treatments such as atropine, orthokeratology, or myopia control glasses/lenses
  • Eye diseases, abnormalities, developmental conditions, or past eye surgeries that could affect refraction or axial length progression
  • Current or past manifest strabismus, amblyopia, or nystagmus
  • Unable to pass eye tracking calibration in at least 50% of cases or to be tracked at least 50% of the time during screening
  • Current or prior use of bifocal lenses, progressive-addition lenses, or multifocal contact lenses
  • Premature birth at 32 weeks gestation or earlier or birth weight under 1500 grams

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kaplan MC

Rehovot, Israel

Actively Recruiting

Loading map...

Research Team

O

Oren Yehezkel, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here